Head-to-head evidence
Henagliflozin vs Yogliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Henagliflozin
Developed by Jiangsu Hengrui Pharmaceuticals
NCT03159052 · Phase 3 · status unknown
This was a randomized, quadruple-blind, placebo-controlled trial (n=450). The primary endpoint, HbA1c change at 24 weeks, was clearly met: both the 5 mg and 10 mg doses reduced HbA1c significantly more than placebo (p<.001 for each).
Next expected readout: December 2026 · NCT06448130 (registry estimate)
Yogliptin
Developed by Chengdu Easton Biopharmaceuticals
NCT05318326 · Phase 3 · status unknown
The trial randomly assigns patients to Yogliptin or a matching placebo and blinds patients, care providers, investigators and outcome assessors alike, using HbA1c change, the standard regulator-accepted measure for diabetes drugs, as its main result. Results have not been posted yet, so whether Yogliptin lowered blood sugar significantly more than placebo is not yet known.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Henagliflozin's landscape · Yogliptin's landscape